182 related articles for article (PubMed ID: 34448362)
1. Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials.
Chen YT; Valent ET; van Beers EH; Kuiper R; Oliva S; Haferlach T; Chng WJ; van Vliet MH; Sonneveld P; Larocca A
Int J Lab Hematol; 2022 Feb; 44(1):127-134. PubMed ID: 34448362
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma.
van Beers EH; van Vliet MH; Kuiper R; de Best L; Anderson KC; Chari A; Jagannath S; Jakubowiak A; Kumar SK; Levy JB; Auclair D; Lonial S; Reece D; Richardson P; Siegel DS; Stewart AK; Trudel S; Vij R; Zimmerman TM; Fonseca R
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):555-562. PubMed ID: 28735890
[TBL] [Abstract][Full Text] [Related]
3. Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translation.
Hermansen NE; Borup R; Andersen MK; Vangsted AJ; Clausen NT; Kristensen DL; Nielsen FC; Gimsing P
Int J Lab Hematol; 2016 Jun; 38(3):298-307. PubMed ID: 27027250
[TBL] [Abstract][Full Text] [Related]
4. International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.
Waheed S; Shaughnessy JD; van Rhee F; Alsayed Y; Nair B; Anaissie E; Szymonifka J; Hoering A; Crowley J; Barlogie B
Cancer; 2011 Mar; 117(5):1001-9. PubMed ID: 20945320
[TBL] [Abstract][Full Text] [Related]
5. Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System.
Kuiper R; van Duin M; van Vliet MH; Broijl A; van der Holt B; El Jarari L; van Beers EH; Mulligan G; Avet-Loiseau H; Gregory WM; Morgan G; Goldschmidt H; Lokhorst HM; Sonneveld P
Blood; 2015 Oct; 126(17):1996-2004. PubMed ID: 26330243
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routine.
Meissner T; Seckinger A; Rème T; Hielscher T; Möhler T; Neben K; Goldschmidt H; Klein B; Hose D
Clin Cancer Res; 2011 Dec; 17(23):7240-7. PubMed ID: 21986844
[TBL] [Abstract][Full Text] [Related]
7. Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial.
Hose D; Beck S; Salwender H; Emde M; Bertsch U; Kunz C; Scheid C; Hänel M; Weisel K; Hielscher T; Raab MS; Goldschmidt H; Jauch A; Moreaux J; Seckinger A
J Hematol Oncol; 2019 Jun; 12(1):65. PubMed ID: 31242924
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients.
González-Calle V; Slack A; Keane N; Luft S; Pearce KE; Ketterling RP; Jain T; Chirackal S; Reeder C; Mikhael J; Noel P; Mayo A; Adams RH; Ahmann G; Braggio E; Stewart AK; Bergsagel PL; Van Wier SA; Fonseca R
Ann Hematol; 2018 Aug; 97(8):1453-1462. PubMed ID: 29623394
[TBL] [Abstract][Full Text] [Related]
9. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.
D'Agostino M; Cairns DA; Lahuerta JJ; Wester R; Bertsch U; Waage A; Zamagni E; Mateos MV; Dall'Olio D; van de Donk NWCJ; Jackson G; Rocchi S; Salwender H; Bladé Creixenti J; van der Holt B; Castellani G; Bonello F; Capra A; Mai EK; Dürig J; Gay F; Zweegman S; Cavo M; Kaiser MF; Goldschmidt H; Hernández Rivas JM; Larocca A; Cook G; San-Miguel JF; Boccadoro M; Sonneveld P
J Clin Oncol; 2022 Oct; 40(29):3406-3418. PubMed ID: 35605179
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation.
Çiftçiler R; Göker H; Demiroğlu H; Haznedaroğlu İC; Sayınalp N; Aksu S; Özcebe O; Büyükaşık Y
Turk J Haematol; 2021 Feb; 38(1):33-40. PubMed ID: 32539315
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.
Anguiano A; Tuchman SA; Acharya C; Salter K; Gasparetto C; Zhan F; Dhodapkar M; Nevins J; Barlogie B; Shaughnessy JD; Potti A
J Clin Oncol; 2009 Sep; 27(25):4197-203. PubMed ID: 19636021
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial.
Kuiper R; Zweegman S; van Duin M; van Vliet MH; van Beers EH; Dumee B; Vermeulen M; Koenders J; van der Holt B; Visser-Wisselaar H; Hansson M; van der Velden AWG; Beverloo HB; Stevens-Kroef M; Levin MD; Broijl A; Waage A; Sonneveld P
Blood Adv; 2020 Dec; 4(24):6298-6309. PubMed ID: 33351127
[TBL] [Abstract][Full Text] [Related]
13. Circulating plasma cells as a predictive biomarker in Multiple myeloma: an updated systematic review and meta-analysis.
Li Q; Ai L; Zuo L; Li J; Zhao F; Xu A; Zhang B; Cai L; Hu Y; Sun C
Ann Med; 2024 Dec; 56(1):2338604. PubMed ID: 38599340
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma.
Mao X; Yan W; Mery D; Liu J; Fan H; Xu J; Xu Y; Sui W; Deng S; Zou D; Du C; Yi S; van Rhee F; Barlogie B; Shaughnessy JD; Anderson KC; Zhan F; Qiu L; An G
Am J Hematol; 2024 Apr; 99(4):523-533. PubMed ID: 38247315
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma.
Ozaki S; Handa H; Saitoh T; Murakami H; Itagaki M; Asaoku H; Suzuki K; Isoda A; Matsumoto M; Sawamura M; Sunami K; Takezako N; Hagiwara S; Kuroda Y; Chou T; Nagura E; Shimizu K
Ann Hematol; 2019 Jul; 98(7):1703-1711. PubMed ID: 31049648
[TBL] [Abstract][Full Text] [Related]
16. Analytical Validation of SKY92 for the Identification of High-Risk Multiple Myeloma.
van Beers EH; Huigh D; Bosman L; de Best L; Kuiper R; Spaan M; van Duin M; Sonneveld P; Dumee B; van Vliet MH
J Mol Diagn; 2021 Jan; 23(1):120-129. PubMed ID: 33152501
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of circulating clonal plasma cells in newly diagnosed multiple myeloma.
Han W; Jin Y; Xu M; Zhao SS; Shi Q; Qu X; Zhang R; Li J; Wu Y; Chen L
Hematology; 2021 Dec; 26(1):510-517. PubMed ID: 34314294
[TBL] [Abstract][Full Text] [Related]
18. The Revised International Staging System Compared to the Classical International Staging System Better Discriminates Risk Groups among Transplant-Ineligible Multiple Myeloma Patients.
Bila J; Jelicic J; Dencic Fekete M; Trajkovic G; Sretenovic A; Perunicic Jovanovic M; Antic D; Mihaljevic B
Oncol Res Treat; 2017; 40(10):616-620. PubMed ID: 28950269
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma.
Kastritis E; Terpos E; Roussou M; Gavriatopoulou M; Migkou M; Eleutherakis-Papaiakovou E; Fotiou D; Ziogas D; Panagiotidis I; Kafantari E; Giannouli S; Zomas A; Konstantopoulos K; Dimopoulos MA
Haematologica; 2017 Mar; 102(3):593-599. PubMed ID: 27789676
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents.
Shang Y; Jin Y; Liu H; Ding L; Tong X; Tu H; Zang L; Lin C; Hu J; Zhou F
Hematol Oncol; 2022 Apr; 40(2):212-222. PubMed ID: 34860428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
